Acrivon AB
Developing targeted cancer therapies using proprietary proteomics platform.
Översikt
- 10–19
- Anställda
- 20–50milj SEK
- Omsättning
- 2018
- Grundat
Nyckelbeslutsfattare
Peter Blume-Jensen
CEO, President, Founder Chairperson
Tiffany Crowell
Head of Clinical Operations
David Proia
Head of Biology and Drug Discovery
Eric Devroe
Chief Operating Officer
+24 fler kontakter i Funnelfeedr
Beskrivning
Acrivon Therapeutics is a clinical-stage oncology company focused on developing targeted therapies to improve patient lives. They utilize their proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which moves beyond traditional genomics. This platform generates unique OncoSignature co...